Talquetamab Plus Pomalidomide Achieves Effective Responses in MonumenTAL-2

The combination of talquetamab and pomalidomide induced rapid and deep responses in patients with relapsed or refractory multiple myeloma and two or more prior lines of therapy, according to data from the phase Ib MonumenTAL-2 trial.

Emma Searle, MD, of the Christie NHS Foundation Trust and the University of Manchester, presented the findings at the Society of Hematologic Oncology 2024 Annual Meeting in Houston, Texas.

Dr. Searle added that talquetamab and pomalidomide yielded robust responses across patient subgroups and had safety “consistent with the individual agents, with low rates of treatment discontinuation due to adverse events (AEs) and no evidence of additive hematologic/cytokine release syndrome (CRS) toxicities.”

The analysis included 35 patients who received pomalidomide 2 mg daily alongside talquetamab at either 0.4 mg/kg once weekly (QW; n=16) or 0.8 mg/kg once every two weeks (Q2W; n=19).

Over a median follow-up of 15.0 months and 11.1 months in the QW and Q2W groups, respectively, the overall response rates were 93.8% and 84.2% and median times to first response were 1.7 months and 1.2 months, respectively. Median duration of response and progression-free survival were not reached.

Among all patients, the most common AEs were taste-related events (85.7%), infections (80%), and CRS (74.3% grade 1/2; one grade 3). Grade 3/4 AEs occurred in 91.4% of patients, most commonly neutropenia (54.3%), anemia (25.7%), infections (22.9%), and thrombocytopenia (20%). Nail toxicities occurred in 68.6% of patients, skin in 74.3%, and rash in 20%, most of which were grade 1/2 with none leading to discontinuation, the authors reported.

“The promising efficacy and manageable safety profile of talquetamab plus pomalidomide support talquetamab as a versatile combination partner,” Dr. Searle and colleagues concluded.

Reference

Searle E, Quach H, Biran N, et al. Talquetamab (Tal), a GPRC5D×CD3 bispecific antibody (BsAb), in combination with pomalidomide (pom) in patients with relapsed/refractory multiple myeloma (RRMM): efficacy and safety results from the phase 1b MonumenTAL-2 study. Abstract #MM-349. Presented at the Society of Hematologic Oncology Annual Meeting; September 4-7, 2024; Houston, Texas.